ClinicalThought
View More
Read this expert commentary discussing a 44-year-old woman with recurring advanced TNBC who received treatment with sacituzumab govitecan, an FDA-approved Trop-2–directed antibody and topoisomerase inhibitor conjugate, in the relapsed/refractory setting.
In this commentary, expert faculty address frequently asked questions about the current optimal treatment of patients with triple-negative breast cancer.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.